Post-earnings recap
Reported
Thu, Feb 15, 2024
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Est. EPS
—
Est. Rev
—
Impl. Move
—
The earnings report indicates that 10X Genomics is facing challenges, particularly reflected in the EPS miss. The stock reacted slightly down by 0.02%, suggesting that investors are cautious. Without revenue figures or guidance, uncertainty remains about the company's near-term prospects.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.41 | N/A | -14.85% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about market conditions impacting performance. They remain committed to their strategic goals.
Management acknowledged challenges in the current market environment.
They emphasized a focus on long-term growth despite short-term setbacks.